These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31686551)

  • 1. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2020 Mar; 23(3):243-251. PubMed ID: 31686551
    [No Abstract]   [Full Text] [Related]  

  • 2. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2019 Oct; 22(10):1055-1062. PubMed ID: 31296074
    [No Abstract]   [Full Text] [Related]  

  • 3. Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.
    Peffault de Latour R; Huynh L; Ivanova JI; Totev T; Bilginsoy M; Antin J; Roy A; Duh MS
    Ann Hematol; 2020 Apr; 99(4):743-752. PubMed ID: 32065291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study.
    Liu L; Han B; Zhang Y; Lei M; Liu R; Lin Z; Jiao W; Zhang F; Fu R; Zhao X; Miao M; Zhang L; Wu D
    Bone Marrow Transplant; 2024 Oct; 59(10):1449-1457. PubMed ID: 39090437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
    Groarke EM; Patel BA; Gutierrez-Rodrigues F; Rios O; Lotter J; Baldoni D; St Pierre A; Shalhoub R; Wu CO; Townsley DM; Young NS
    Br J Haematol; 2021 Feb; 192(3):605-614. PubMed ID: 33410523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag in children with severe aplastic anemia.
    Lesmana H; Jacobs T; Boals M; Gray N; Lewis S; Ding J; Kang G; Hale M; Weiss M; Reiss U; Wang W; Wlodarski M
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29066. PubMed ID: 33855784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiating immunoglobulin replacement therapy helps reduce severe infections and shifts healthcare resource utilization to outpatient services among US patients with inborn errors of immunity.
    Riaz F; Umashankar K; Marchlewicz EH; Zhang K; Khandelwal N; Sanchirico M
    J Med Econ; 2024; 27(1):849-857. PubMed ID: 38885115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avatrombopag as alternative therapy for severe aplastic anemia patients who are intolerant or unresponsive to eltrombopag.
    Zhang T; Yu Q; Chen X; Yang H; Gong Y; Zhang Y; Liu X; Yang Z; Fang Y; Yan X; Zhou X; Shi J; He G
    Front Immunol; 2024; 15():1393829. PubMed ID: 39114665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
    Huang LF; Li L; Jia JS; Yang Y; Lin SY; Meng FK; Zhang DH; He GS
    Transplant Cell Ther; 2022 Sep; 28(9):586.e1-586.e7. PubMed ID: 35609866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource utilization and costs associated with hepatitis A in the United States: a retrospective database analysis.
    Samant S; Chen E; Carias C; Kujawski SA
    J Med Econ; 2024; 27(1):1046-1052. PubMed ID: 39092467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
    Patel BA; Groarke EM; Lotter J; Shalhoub R; Gutierrez-Rodrigues F; Rios O; Quinones Raffo D; Wu CO; Young NS
    Blood; 2022 Jan; 139(1):34-43. PubMed ID: 34525188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.
    Liu L; Lei M; Fu R; Han B; Zhao X; Liu R; Zhang Y; Jiao W; Miao M; Zhang F; Zhang L; Wu D
    J Hematol Oncol; 2022 Aug; 15(1):105. PubMed ID: 35962406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia.
    Jin Y; Li R; Lin S; Jia J; Yang Y; Zhang D; He G; Li J
    Ann Hematol; 2022 Nov; 101(11):2413-2419. PubMed ID: 36028583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy.
    Hwang YY; Chan TSY; Chan FHY; Lau CWP; Luk YY; Lau GWN; Chan KP; Leung KH; Kho B; Lau JSM; Lau CK; Mak V; Yip SF; Lin SY; Sim JPY; Kwong YL
    Ann Hematol; 2022 Jun; 101(6):1163-1172. PubMed ID: 35412083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
    Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
    Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia.
    Patwardhan P; Proudman D; Allen J; Lucas S; Nellesen D
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1447-1456. PubMed ID: 34278835
    [No Abstract]   [Full Text] [Related]  

  • 18. Healthcare resource utilization and direct medical costs associated with index and recurrent
    Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
    J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
    [No Abstract]   [Full Text] [Related]  

  • 19. Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias.
    Fan X; Desmond R; Winkler T; Young DJ; Dumitriu B; Townsley DM; Gutierrez-Rodrigues F; Lotter J; Valdez J; Sellers SE; Barranta ME; Shalhoub RN; Wu CO; Albitar M; Calvo KR; Young NS; Dunbar CE
    Blood Adv; 2020 Apr; 4(8):1700-1710. PubMed ID: 32330244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis.
    Zhang Y; Li J; Li X; Geng Q; Xie Y; Zhang G; Wei M; Ma Y
    Syst Rev; 2024 Apr; 13(1):101. PubMed ID: 38576005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.